The complaint centers on claims that Immutep violated the Securities Exchange Act by obscuring the true performance of its eftilagimod alfa, or efti, treatment. While a January 30, 2026, SEC filing touted strong operational progress for the TACTI-004 trial, the suit alleges leadership already knew the study would fail to meet its primary endpoints. This discrepancy purportedly led to artificial inflation of the company's market valuation.

Affected parties have until July 6, 2026, to contact Brian Schall of the Los Angeles-based firm to discuss potential recovery of losses. Because the class has not yet reached legal certification, investors currently remain absent members without formal representation. Those seeking to participate in the pending litigation can reach the firm at 310-301-3335 or via their website to review their legal standing.